Are Rates of Colectomies, Resections, Mortalities and Cancer Reduced by Home Monitoring of IBD Patients ?
NCT ID: NCT03038984
Last Updated: 2022-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
120 participants
INTERVENTIONAL
2016-08-31
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Is Relapse Rate Reduced by Home Monitoring of IBD Patients Tightly or on Demand by FC and Disease Activity?
NCT02492555
IBD Self-management Website and Home Faecal Calprotectin Monitoring
NCT03671980
Remote Monitoring of IBD
NCT05886322
TOD-IBD: Empowering Patients On-Demand
NCT06179563
Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
NCT02542917
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At the out-patient consultation IBD patients has been informed about the project and the IBD eHealth nurse has ensured that no exclusion criteria was met by the patients.
Inclusion criteria:
IBD patients in remission, SCCAI ≤ 2 (Simple Clinical Colitis Activity Index )) or HBI \< 5 (Harvey \& Bradshaw Activity Index ) or in mild to moderate disease activity ( SCCAI 3-4, HBI \< 16) IBD patients who can read, speak and understand Danish. IBD patients that can take advantage of the Internet and wireless network. 18 years or older.
Exclusion criteria:
IBD patients with severe disease activity HB \> 16 SCCAI ≥ 5 IBD patients with social, medical or psychological issues of a more complex character. IBD patients with particularly complex issues such as drug and alcohol problems, severe mental / psychiatric disorders and / or serious social impact.IBD patients who cannot attend due language barrier or cognitive disorder. Age less than 18.
When the patient has agreed to participate in the study, randomized to either OD or 3. Months (This has been done ClinicalTrials.gov ID: NCT02492555)
Patients log in to www.noh.constant-care.dk at least once every 3rd months throughout the project period of 11 years in total (2015-2026). When the patient log in to the telemedicine platform the following scorings must be filled out:
1. \- Disease activity (DA), respectively SCCAI or HBI.
2. \- Quality of life assessment, s-IBDQ
3. \- FACIT (Fatigue score)
4. \- MARS ( Medical Adherence Rating Scale)
5. \- FC, fecal calprotectin mg / kg measured by the patient's own SMART phone, rapid home test.
If the patients prefer to send the fecal samples for test, it will be analyzed in the ehealth gastro lab. at the hospital with a SMART phone as well.
The results of the scoring systems will appear to the health care professionals and patients in a traffic light manner (red, yellow and green).
If the patient experiences a recurrence of the disease, it moves from green to either yellow or red area in the traffic graph, and patient will further be instructed to contact Gastro medical clinic project nurse for an early consultation and decision on further treatment initiative. This will also be indicated at the patient's website. If alarm symptoms occurs patients are instructed to contact the project nurse. Thus patients are treated in accordance to national and international guideline. By screening of the inflammation burden (web algorithm), the decision is moving forward.
Patients logging in on demand, indicate disease activity, quality of life and FC at the start, and subsequently when needed and at the end of the study (after 11 years from inclusion).
At relapse, disease activity score and FC is settled and repeated no later than 7 days here after. When the patient has reached remission (green) a new DA and FC test should be performed to verify the remission.
The purpose of this study is to determine if the IBD patients doing home monitoring have relative reduced rates of colectomies, resections, mortalities and cancer after 11 years of web monitoring. Relative reduced rates of colectomies etc. means - relative to standard care but also if there is a difference between the two web screening procedures on these endpoints.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Every 3 months
screening every 3rd month: (home monitoring: FC and DA)
At Home Screening procedure every 3 months
Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
On demand
screening On demand: (home monitoring: FC and DA)
At Home Screening procedure On demand
Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
At Home Screening procedure On demand
Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand
At Home Screening procedure every 3 months
Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nordsjaellands Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dorit Vedel Ankersen
PhD student, Msc food science and Msc Clinical nutrition
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pia Munkholm, Professor
Role: STUDY_DIRECTOR
North Zealand University Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-15005603
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.